China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)
(Incorporated in Bermuda with limited liability)
(Stock Code: 673)

(1) RESULTS OF THE VALID ACCEPTANCES OF THE RIGHTS SHARES; AND (2) NUMBER OF THE UNSUBSCRIBED RIGHTS SHARES SUBJECT TO THE COMPENSATORY ARRANGEMENTS

Reference is made to the prospectus (the "**Prospectus**") of China Health Group Limited (the "**Company**") dated 3 September 2025 in relation to the Rights Issue on the basis of three (3) Rights Shares for every ten (10) Shares held on the Record Date at the Issue Price of HK$0.10 per Rights Share. Capitalised terms used herein shall have the same meanings as those defined in the Prospectus unless the context otherwise requires.

RESULTS OF THE VALID ACCEPTANCES OF THE RIGHTS SHARES

The total number of Rights Shares offered under the Rights Issue is 147,493,428.

The Board announces that as at 4:00 p.m. on Wednesday, 17 September 2025, being the Latest Time for Acceptance, a total of 10 valid acceptances for a total of 119,689,791 Rights Shares had been received, representing approximately 81.1% of all the Rights Shares. Accordingly, the Rights Issue was undersubscribed by 27,803,637 Rights Shares, representing approximately 18.9% of all the Rights Shares, which will be subject to the Compensatory Arrangements.

Pursuant to the Deed of Covenants and Undertaking, Mr. Zhang and the Underwriter subscribed for 392,220 and 40,797,600 Rights Shares respectively.

THE COMPENSATORY ARRANGEMENTS

Pursuant to the Listing Rules, the Company had made arrangements to dispose of the Unsubscribed Rights Shares by offering the Unsubscribed Rights Shares to the Placees for the benefit of the relevant No Action Shareholders to whom they were offered under the Rights Issue.

The Company appointed the Placing Agent to place the Unsubscribed Rights Shares after the Latest Time for Acceptance to the Placees on a best effort basis, and the Net Gain (being any premium over the aggregate amount of (i) the Issue Price for those Rights Shares; and (ii) the expenses of the Placing Agent (including any other related costs and expenses), that is realised from the Placing) will be paid to those No Action Shareholders in the manner set out below. The Placing Agent will, on a best effort basis, procure, by not later than 4:00 p.m. on Wednesday, 24 September 2025, acquirers of those Unsubscribed Rights Shares at a price not less than the Issue Price. Any unsold Unsubscribed Rights Shares under the Compensatory Arrangements will be taken up by the Underwriter pursuant to the terms of the Underwriting Agreement.

Net Gain (if any) will be paid on a pro-rata basis to the No Action Shareholders (but rounded down to the nearest cent) as set out below:

(a) where the nil-paid rights are, at the time they lapse, represented by a PAL, to the person whose name and address appeared on the PAL; and

(b) where the nil-paid rights are, at the time they lapse, registered in the name of HKSCC Nominees Limited, to the beneficial holders (via their respective CCASS participants) as the holder of those nil-paid rights in CCASS.

If the Net Gain to any of the No Action Shareholder(s) mentioned above (i) is more than HK$100, the entire amount will be paid to them; or (ii) is HK$100 or less, such amount will be retained by the Company for its own benefit.

An announcement of the results of the Rights Issue (including the results of the Placing and the Net Gain) is expected to be published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.ch-groups.com) on Thursday, 2 October 2025.

Any changes to the expected timetable will be announced by way of an announcement by the Company as and when appropriate.

WARNINGS

Shareholders and potential investors of the Company should note the Rights Issue is subject to, among other things, the fulfillment and/or waiver (as the case may be) of a number of conditions precedent set out in the paragraph headed "Conditions of the Rights Issue and the Underwriting Agreement" of the section headed "The Underwriting Agreement" in the "Letter from the Board" contained in the Prospectus, and therefore may or may not materialise and proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares and securities of the Company. Any party who is in any doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional adviser(s).

By order of the Board
China Health Group Limited
Chung Ho
Chief Executive Officer and Executive Director

Hong Kong, 22 September 2025

As of the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (Chairman), Mr. Chung Ho and Mr. Xing Yong; two non-executive Directors, namely, Mr. Huang Lianhai and Mr. Wang Jingming; and four independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua, Mr. Lai Liangquan and Ms. Yang Huimin.